Prof. Max

Biography

Career History Sept 2017-present: Professor of Glycobiology. University of Southampton, UK. Oxford Glycobiology Institute, University of Oxford May 2013-Aug 2017: Principal Investigator, Glycoprotein Therapeutics Laboratory Dec 2011-Aug 2017: University Research Lecturer Feb 2009-May 2013: Senior Research Associate, Laboratory of Dr Chris Scanlan Corpus Christi College, Oxford Sep 2014-Aug 2017: Stipendiary Lectureship in Biochemistry, Director of Studies (Biochemistry) Oriel College, Oxford Feb 2017 - Aug 2017: Senior Dean Sep 2014 - Aug 2017: Against Breast Cancer Senior Research Fellow Sep 2008 - Aug 2014: Fellow and Tutor in Biochemistry Sep 2007 - Aug 2008: Lecturer in Biochemistry, Director of Studies (Biochemistry) Division of Structural Biology, University of Oxford Feb 2006 - Feb 2009: Post-doc, Laboratories of Prof. E.Y. Jones FRS & Prof. D.I. Stuart FRS Academic Qualifications 2001-2005: DPhil in Biochemistry. University of Oxford, UK. Career History Sept 2017-present: Professor of Glycobiology. University of Southampton, UK. Oxford Glycobiology Institute, University of Oxford May 2013-Aug 2017: Principal Investigator, Glycoprotein Therapeutics Laboratory Dec 2011-Aug 2017: University Research Lecturer Feb 2009-May 2013: Senior Research Associate, Laboratory of Dr Chris Scanlan Corpus Christi College, Oxford Sep 2014-Aug 2017: Stipendiary Lectureship in Biochemistry, Director of Studies (Biochemistry) Oriel College, Oxford Feb 2017 - Aug 2017: Senior Dean Sep 2014 - Aug 2017: Against Breast Cancer Senior Research Fellow Sep 2008 - Aug 2014: Fellow and Tutor in Biochemistry Sep 2007 - Aug 2008: Lecturer in Biochemistry, Director of Studies (Biochemistry) Division of Structural Biology, University of Oxford Feb 2006 - Feb 2009: Post-doc, Laboratories of Prof. E.Y. Jones FRS & Prof. D.I. Stuart FRS Academic Qualifications 2001-2005: DPhil in Biochemistry. University of Oxford, UK.

Research Interest

In the Glycoprotein Therapeutics Laboratory we exploit the glycan modifications of proteins in the design of vaccines candidates and glycoprotein-based therapeutics. We have a particular interest in vaccine design against the Human Immunodeficiency Virus (HIV) and in the development of novel antibody-based cancer therapeutics. This involves understanding how glycans impact on protein and viral function, how they are structured, and how we they can be manipulated for therapeutic applications.